A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

Purpose

The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.

Condition

  • Healthy Volunteers

Eligibility

Eligible Ages
Between 18 Years and 55 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Female individuals not of childbearing potential and males. - Healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments. - 18 to 55 years of age, inclusive, at the time of signing the informed consent with a BMI 18.0 to 32.0 kg/m2, inclusive. - Other protocol-defined Inclusion/

Exclusion Criteria

apply.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Treatment A
  • Drug: BMS-986278
    Specified dose on specified days
Experimental
Treatment B
  • Drug: BMS-986278
    Specified dose on specified days
  • Drug: Placebo
    Specified dose on specified days
Placebo Comparator
Treatment C
  • Drug: Placebo
    Specified dose on specified days
Experimental
Treatment D
  • Drug: Placebo
    Specified dose on specified days
  • Drug: Moxifloxacin
    Specified dose on specified days

Recruiting Locations

Worldwide Clinical Trials
San Antonio, Texas 78217
Contact:
Alan Hand, Site 0001
210-635-1515

More Details

Status
Recruiting
Sponsor
Bristol-Myers Squibb

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com